The PAC 1 receptor and tissue transglutaminase (TG2) play important roles in neurite outgrowth and modulation of neuronal cell survival. In this study, we investigated the regulation of TG2 activity by the PAC 1 receptor in retinoic acid-induced differentiating N2a neuroblastoma cells. TG2 transamidase activity was determined using an amine incorporation and a peptide cross linking assay. In situ TG2 activity was assessed by visualising the incorporation of biotin-X-cadaverine using confocal microscopy. TG2 phosphorylation was monitored via immunoprecipitation and Western blotting. The role of TG2 in PAC 1 receptor-induced cytoprotection and neurite outgrowth was investigated by monitoring hypoxiainduced cell death and appearance of axonal-like processes, respectively. The amine incorporation and protein crosslinking activity of TG2 increased in a time and concentration-dependent manner following stimulation with pituitary adenylate cyclase-activating polypeptide-27 (PACAP-27). PACAP-27 mediated increases in TG2 activity were abolished by the TG2 inhibitors Z-DON and R283 and by pharmacological inhibition of protein kinase A (KT 5720 and Rp-cAMPs), protein kinase C (Ro 31-8220), MEK1/2 (PD 98059), and removal of extracellular Ca
Introduction
Transglutaminases (TGs) are a family of Ca 2+ -dependent enzymes that catalyse the post-translational modification of proteins (for extensive reviews see [54, 20] ). There are eight distinct catalytically active members of the TG family which exhibit differential expression (Factor XIIIa and TGs 1-7). The ubiquitously expressed TG2 is the most widely studied member of the TG family which is involved in the regulation of numerous cellular processes, including cell adhesion, migration, growth, survival, apoptosis, differentiation, and extracellular matrix organization [54] . In neuronal cells, TG2 is involved in neural differentiation, neurite outgrowth and neuroprotection following cerebral ischaemia [69, 22, 72] .
Transglutaminase 2 (TG2) possesses multiple enzymic functions that include transamidation, protein disulphide isomerase and protein kinase activity [25] . The transamidase activity of TG2 is inhibited by GTP/GDP and evidence suggests that TG2 when bound to GTP/GDP functions as a G-protein (known as Gh; [46] ), which is independent of its transamidase activity. Indeed, several members of the G-protein coupled receptor (GPCR) family including the a 1B -adrenergic receptor, thromboxane A2 receptor and oxytocin receptor couple to Gh when activated, promoting exchange of GDP for GTP [25] . Activated Gh-GTP stimulates phospholipase C d1 promoting phosphoinositide hydrolysis and stimulating increases in intracellular Ca 2+ . The activity of TG2 and other TG family members can be regulated by protein kinases. For example, phosphorylation of TG2 by protein kinase A (PKA) inhibits its transamidating activity but enhances its kinase activity [49] . The transamidating activity of TG1 (keratinocyte transglutaminase) is enhanced by phorbol ester-induced stimulation of protein kinase C (PKC) and extracellular signal-regulated kinase 1/2 (ERK1/2; [7] . These findings suggest that the activity of TG can be regulated by signalling pathways associated with GPCRs. However, the regulation of intracellular TG2 following stimulation of GPCRs is not well understood. Examples include muscarinic receptor-mediated increases in TG2 activity in SH-SY5Y cells [78] , 5-HT 2A receptor-mediated transamidation of Rac1 in the rat A1A1v cortical cell line [13] and A 1 adenosine receptor-mediated increases in TG2 transamidase activity in rat H9c2 cardiomyoblasts [74] .
Of particular interest to the current study is pituitary adenylate cyclase-activating polypeptide (PACAP), which is widely distributed in the brain and peripheral organs and displays high affinity for the PAC 1 receptor [73] . The PAC 1 receptor is a member of the GPCR superfamily which activates adenylyl cyclase/cAMP/PKA (via G s -protein coupling) and phospholipase C/DAG/PKC (via G qprotein coupling) dependent signalling pathways [18, 73] . The PAC 1 receptor also triggers the activation of several other protein kinase cascades such as ERK1/2, JNK1/2, p38 MAPK and PKB [51, 44, 8] . Since some of these protein kinase pathways are associated with modulation of TG activity (PKA, PKC and ERK1/2) it is conceivable that the PAC 1 receptor regulates TG activity. Since mouse N2a neuroblastoma cells express PAC 1 receptors [39, 50] the primary aims of this study were (i) to determine whether the PAC 1 receptor modulates TG2 activity in these cells and (ii) to assess the role of TG2 in PAC 1 receptor-induced neuroprotection and neurite outgrowth. The results obtained indicate that PAC 1 receptor stimulation triggers TG2-mediated amine incorporation and protein cross-linking activity in differentiating N2a and SH-SY5Y cells. Furthermore, inhibition of TG2 attenuates PAC 1 receptor-induced cytoprotection and neurite outgrowth.
Materials and methods

Materials
Akt inhibitor XI, KT 5720, Ro-31-8220 and Rp-8-Cl-cAMPS (adenosine 3 0 ,5 0 -cyclic monophosphorothioate, 8-chlro-, Rp-isomer) were purchased from Calbiochem (San Diego, CA). [Ala 11, 22, 28 ]-VIP, Bay 55-9837, PACAP-27, PACAP 6-38, PD 98059, SB 203580, and SP 600 125 were obtained from Tocris Bioscience (Bristol, UK). All-trans retinoic acid, casein, Protease Inhibitor Cocktail (for use with mammalian cell and tissue extracts), Phosphatase Inhibitor Cocktail 2 and 3, ExtrAvidin Ò -HRP and ExtrAvidin Ò -FITC were obtained from Sigma-Aldrich Co. Ltd. (Gillingham, UK). The TG2 inhibitors Z-DON (Z-DON-Val-Pro-Leu-OMe) and R283, together with purified guinea-pig liver TG2 were obtained from Zedira GmbH (Darmstadt, Germany). DAPI was from Vector Laboratories Inc (Peterborough, UK). Fluo-8/AM was purchased from Stratech Scientific Ltd (Newmarket, UK). Biotin-TVQQEL was purchased from Pepceuticals (Enderby, UK). Biotin cadaverine (N-(5-aminopentyl)biotinamide) and biotin-X-cadaverine (5-([(N-(bioti noyl)amino)hexanoyl]amino)pentylamine) were purchased from Invitrogen, UK. Dulbecco's modified Eagle's medium (DMEM), foetal bovine serum, trypsin (10Â), L-glutamine (200 mM), penicillin (10,000 U/ml)/streptomycin (10,000 lg/ml) were purchased from ), polyclonal anti-total PKB, monoclonal antitotal ERK1/2, monoclonal anti-phospho p38 MAPK, polyclonal anti-total p38 MAPK, monoclonal anti-phospho JNK1/2, polyclonal anti-total JNK1/2 and polyclonal anti-cleaved caspase 3 from New England Biolabs Ltd (UK); polyclonal anti-human keratinocyte TG1 and polyclonal anti-human epidermal TG3 from Zedira GmbH (Darmstadt, Germany); monoclonal anti-TG2 (CUB 7402) from Thermo Scientific (Leicestershire, UK); monoclonal anti-GAPDH, polyclonal anti-phosphoserine and polyclonal antiphosphothreonine from Abcam (Cambridge, UK); polyclonal anti-choline acetyltransferase from Santa Cruz Biotechnology Inc (Heidelberg, Germany).
Cell culture
Murine N2a and human SH-SY5Y neuroblastoma cells were obtained from the European Collection of Animal Cell Cultures (Porton Down, Salisbury, UK). Cells were cultured in DMEM supplemented with 2 mM L-glutamine, 10% (v/v) foetal bovine serum, penicillin (100 U/ml) and streptomycin (100 lg/ml). Cells were maintained in a humidified incubator (95% air/5% CO 2 at 37°C) until 70-80% confluent and sub-cultured (1:5 split ratio) every 3-4 days. SH-SY5Y cells were sub-cultured using trypsin (0.05% w/v)/EDTA (0.02% w/v). Differentiation of N2a cells was induced by culturing cells in serum-free DMEM containing 1 lM all-trans retinoic acid for 48 h, unless otherwise specified. Differentiation of SH-SY5Y cells was induced by culturing cells in serum-free DMEM containing 10 lM all-trans retinoic acid for 5 days. Experiments were performed on passage numbers 8-20 for N2a and 18-25 for SH-SY5Y.
cAMP accumulation assay
N2a cells (5000 cells well À1 ) were seeded on a white 96 well microtitre plate, with clear bottomed wells (Corning; Fisher Scientific, Loughborough, UK) and induced to differentiate as described above. The medium was then removed and the monolayer treated with a range of concentrations of PACAP-27 for 20 min in serumfree DMEM (40 ll well À1 ) in the presence of 20 mM MgCl 2 and 500 lM 3-isobutyl-1-methylxanthine (IBMX). Following stimulation, cAMP levels within cells were determined using the cAMPGlo TM Max Assay kit (Promega; Southampton, UK). Briefly, 10 ll of cAMP detection solution was added to all wells and incubated for 20 min at room temperature. After incubation, Kinase-Glo Ò reagent (50 ll well À1 ) was added and incubated for 10 min at room temperature, following which luminescence levels across the plate were recorded using a plate-reading FLUOstar Optima luminometer (BMG Labtech Ltd, UK,). Treatment with forskolin (10 lM)
was used as a positive control and the luminescence values were converted to cAMP levels using a cAMP standard curve (0-100 nM), according to the manufacturer's instructions.
Cell extraction for measurement of TG2 activity
Time course profiles and concentration-response curves were obtained for PACAP-27. Where appropriate, cells were also preincubated for 30 min in medium with or without the protein kinase inhibitors Rp-cAMPs (PKA, 50 lM; [15] ), KT 5720 (PKA, 5 lM; [31] ), Akt inhibitor XI (PKB/Akt, 100 nM; [2] ), PD 98059 (MEK1/2, 50 lM; [19] ), SP 600125 (JNK1/2, 20 lM; [5] ), and Ro 31-8220 (PKC, 10 lM; [14] ) prior to treatment with 100 nM PACAP-27. The concentrations of protein kinase inhibitors employed in this study were in the range of values in the literature that are used to inhibit the cellular activity of these kinases: KT 5720 (2-10 lM; [77, 43] ); Rp-cAMPs (10-100 lM; [77] ); [43, 76, 56, 71] ; Ro 31-8220 1-10 lM; [37, 52] , PD 98059 (10-50 lM; [66, 33] ), SP 600125 (20 lM; [26, 32] ) and Akt inhibitor XI (1 lM; [23, 59] ). In the case of less well known Akt inhibitor XI effects on PKB inhibition were verified by Western blot analysis.
Following stimulation, N2a and SH-SY5Y cells were rinsed twice with 2.0 ml of chilled PBS, lysed with 500 ll of ice-cold lysis buffer (50 mM Tris-HCl pH 8.0, 0.5% (w/v) sodium deoxycholate, 0.1% (v/ v) Protease Inhibitor Cocktail, and 1% (v/v) Phosphatase Inhibitor Cocktail 2). Cell lysates were scraped and clarified by centrifugation at 4°C for 10 min at 14000g prior to being assayed for TG activity using the biotin-labeled cadaverine incorporation assay (see below). Supernatants were collected and stored at À80°C. Protein levels were determined by the bicinchoninic acid (BCA) protein assay, based on the method of Smith et al. [63] , which was performed using a commercially available kit (Sigma-Aldrich, UK) using bovine serum albumin (BSA) as the standard. Transglutaminase activity was monitored by two different transamidase assays; amine incorporation and protein cross-linking.
Biotin-labeled cadaverine incorporation assay
The assay was performed as per the method described by Slaughter et al. [62] with the modifications of Lilley et al. [40] . . Each experiment was performed in triplicate.
Biotin-labeled peptide-cross-linking assay
The assay was performed according to the method of Trigwell et al. [70] with minor modifications. Microtitre plates (96-well) were coated and incubated overnight at 4°C with casein at 1.0 mg ml À1 in 100 mM Tris-HCl pH 8.0 (250 ll per well). The wells were washed twice with distilled water, before incubation at room temperature for 1 h with 250 ll of blocking solution (100 mM TrisHCl pH 8.0 containing 3% (w/v) BSA). The plate was washed twice before the application of 150 ll of either 6.67 mM calcium chloride and or 13.3 mM EDTA assay buffer containing 5 lM biotin-TVQQEL and 2 mM 2-mercaptoethanol. The reaction was started by the addition of 50 ll of samples or positive control (50 ng/well of guinea-pig liver TG2) and negative control (100 mM Tris-HCl, pH 8.0) and allowed to proceed for 1 h at 37°C. Reaction development and termination were performed as described for biotincadaverine assays. One unit of TG2 was defined as a change in absorbance of one unit h
À1
. Each experiment was performed in triplicate.
Hypoxia-induced cell death
Differentiating N2a and SH-SY5Y cells in glucose-free and serum-free DMEM (Gibco TM , Life Technologies Ltd, Paisley, UK) were exposed to hypoxia using a hypoxic incubator (5% CO 2 /1% O 2 at 37°C) in which O 2 was replaced by N 2 .
Cell viability assays
N2a and SH-SY5Y cells were plated in 24-well flat bottomed plates (15,000 cells/well) and differentiated for 48 h, before cell viability was determined by measuring the reduction of MTT [53] . The amount of DMSO-solubilised reduced formazan product was determined by measurement of absorbance at a wavelength of 570 nm. Alternatively, cells were plated in 96-well flat bottomed plates (5000 cells per well) and differentiated for 48 h. Following normoxia/hypoxia exposure, the activity of lactate dehydrogenase (LDH) released into the culture medium was detected using the CytoTox 96 Ò non-radioactive cytotoxicity assay (Promega, Southampton, UK) with measurement of absorbance at 490 nm.
Outgrowth of axon-like processes
The outgrowth of axon-like processes in N2a cells was assessed as described previously [27] . N2a cells were seeded in 24-well plates (25,000 cells/well) and incubated for 24 h in growth medium prior to treatment with PACAP-27 (100 nM) in serum-free DMEM for 24 or 48 h. After stimulation, the cells were washed with ice cold phosphate buffered saline (PBS) then fixed in 90% (v/v) methanol in PBS at À20°C for 15 min. After washing, the cells were stained for 1 min at room temperature with Coomassie brilliant blue, washed with PBS then with distilled water. The outgrowth of axon-like processes was morphologically assessed using an inverted light microscope. Five randomly selected fields, containing at least 200 cells, were examined in each well. The total number of cells and the number of axon-like processes, defined as extensions greater than two cell body diameters in length with an extension foot [35] were recorded.
Western blot analysis
Protein extracts (15) (16) (17) (18) (19) (20) lg per lane) were separated by SDS-PAGE (10% w/v polyacrylamide gel) using a Bio-Rad Mini-Protean III system. Proteins were transferred to nitrocellulose membranes in a Bio-Rad trans-Blot system using 25 mM Tris, 192 mM glycine pH 8.3 and 20% (v/v) MeOH). Following transfer, the membranes were washed with Tris-buffered saline (TBS) and blocked for 1 h at room temperature with 3% (w/v) skimmed milk powder in TBS containing 0.1% (v/v) Tween-20. Blots were then incubated overnight at 4°C in blocking buffer with primary antibodies to the following targets (1:1000 dilutions unless otherwise indicated): phospho-specific ERK1/2, phospho-specific PKB (1:500), phosphospecific p38 MAPK, phospho-specific JNK (1:500), cleaved active caspase-3 (1:500), GAPDH, TG1, TG2 or TG3. The primary antibodies were removed and blots washed three times for 5 min in TBS/ Tween 20. Blots were then incubated for 2 h at room temperature with the appropriate secondary antibody (1:1000) coupled to horseradish peroxidase (New England Biolabs Ltd; UK) in blocking buffer. Following removal of the secondary antibody, blots were extensively washed as above and developed using the Enhanced Chemiluminescence Detection System (Uptima, Interchim, France) and quantified by densitometry using Advanced Image Data Analysis Software (Fuji; version 3.52). The uniform transfer of proteins to the nitrocellulose membrane was routinely monitored by transiently staining the membranes with Ponceau S stain prior to application of the primary antibody. When assessing protein kinase phosphorylation samples from each experiment were also analysed on separate blots using primary antibodies that recognise total ERK1/2, PKB, p38 MAPK and JNK1/2 (all 1:1000 dilution) in order to confirm the uniformity of protein loading.
Visualisation of in situ TG2 activity and neuronal markers
N2a cells were seeded on 8-well chamber slides (15,000 cells well À1 ) and differentiated for 48 h in serum-free DMEM containing retinoic acid or PACAP-27 (100 nM). The medium was then removed, monolayer gently washed with PBS and Table overlay provided by the software. Image analysis and quantification were carried out using Leica LAS AF software.
Measurement of intracellular calcium
N2a cells were plated in 24-well flat-bottomed plates (15,000 cells well
À1
) and differentiated for 48 h. Cells were loaded with Manheim, Germany) equipped with a 20Â air objective. Cells were incubated at 37°C using a temperature controller and micro incubator (The Cube, Life Imaging Services, Basel, Switzerland) in the presence of imaging buffer (134 mM NaCl, 6 mM KCl, 1.3 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, and 10 mM glucose; pH 7.4). Using an excitation wavelength of 490 nm, emissions over 514 nm were recorded. Images were collected every 1.7 s for 10 min. Relative increases in intracellular Ca 2+ were defined as F/ F 0 where F was the fluorescence at any given time, and F 0 was the initial basal level of Ca 2+ . . Cell lysates were clarified by centrifugation (4°C for 10 min at 14000g), after which 500 lg of supernatant protein were incubated overnight at 4°C with 2 lg of anti-TG2 monoclonal antibody or IgG control. Immune complexes were precipitated using Pierce TM Classic Magnetic IP/Co-IP Kit (Loughborough, UK). The precipitates were resolved by SDS-PAGE and Western blotting, then probed using anti-phosphoserine or anti-phosphothreonine antibodies (1:1000). Antibody reactivity was visualised by ECL and quantified densitometrically, as described above.
Determination of TG2 phosphorylation
Statistical analysis
All graphs and statistics (one-way ANOVA followed by Dunnet's multiple comparison test and two-way ANOVA for group compar- 
Results
Characterisation of cholinergic neuronal phenotype and TG expression pattern in N2a cells
Mouse N2a neuroblastoma cells can be differentiated into various neuronal types dependent upon the method used [41, 67] . For example, serum withdrawal in the presence of retinoic acid induces differentiation into cholinergic neurons, whereas dibutyryl cAMP promotes the development of dopaminergic neurons [41, 67] . In this study N2a cells were induced to differentiate using retinoic acid in order to avoid potential problems using dibutyryl cAMP when assessing functional responses mediated by the G s -protein coupled PAC 1 receptor. Immunocytochemical staining indicated that expression of the cholinergic neuronal marker, choline acetyltransferase increased markedly after 48 h confirming that retinoic acid promotes differentiation of N2a cells into cholinergic neurons (Fig. 1A and B) .
Western blot analysis was performed to compare the expression of TG isoforms in mitotic and differentiating N2a cells. TG1, TG2 and TG3 expression increased significantly in N2a cells following differentiation for 48 h with 1 lM all-trans retinoic acid ( Fig. 1C and D) . These observations are in agreement with previous studies [12] . (Fig. 2) . The selective VPAC 1 and VPAC 2 agonists, [Ala 11, 22, 28 ]-VIP (1 lM) and Bay 55-9837 (1 lM) respectively, had no significant effect on cAMP accumulation (data not shown). PACAP-27 treatment produced transient increases in TG2 catalysed biotin-cadaverine incorporation and protein crosslinking activity, peaking at 10 min (Fig. 3A and C) . Furthermore, as shown in Fig. 3 , PACAP-27 stimulated concentrationdependent increases in biotin-amine incorporation activity (EC 50 cross-linking activity (EC 50 = 0.4 ± 0.2 nM; p[EC 50 ] = 9.7 ± 0.2; n = 6). The selective PAC 1 receptor antagonist PACAP 6-38 attenuated PACAP-27 induced biotin-amine incorporation activity (Fig. 4A) and protein cross-linking activity (Fig. 4B) . The selective VPAC 1 and VPAC 2 agonists, [Ala 11, 22, 28 ]-VIP (1 lM) and Bay 55-9837 (1 lM) respectively, had no significant effect on TG2 activity (data not shown). Overall, these data indicate that the PAC 1 receptor is functionally expressed and stimulates TG2-mediated transamidase activity in differentiated N2a cells.
Effect of TG2 inhibitors on PAC 1 receptor induced TG2 activity
To confirm that TG2 is responsible for PAC 1 receptor-mediated transglutaminase activity in differentiating N2a cells, two structurally different cell permeable TG2 specific inhibitors were tested; R283 (a small molecule; [24] ) and Z-DON (peptide-based; [60] ).
N2a cells were pre-treated for 1 h with Z-DON (150 lM) or R283 (200 lM) prior to stimulation with PACAP-27 for 10 min. Both inhibitors completely blocked PACAP-27-induced TG-mediated amine incorporation (Fig. 4C) and protein cross-linking activity (Fig. 4D) . It is important to note that despite these TG2 inhibitors being cell-permeable, inhibition of cellular TG2 is only achieved at concentrations significantly above their IC 50 value versus purified enzyme [60, 24] . Overall, these data indicate that TG2 is the TG isoform activated by the PAC 1 receptor.
The effect of protein kinase inhibitors on PAC 1 receptor-induced TG2 activity
Pre-treatment with the PKA inhibitors KT 5720 (5 lM) and RpcAMPs (50 lM) completely abolished PACAP-27-induced amine incorporation (Fig. 4E) and protein cross-linking activity (Fig. 4F) , confirming the involvement of PKA in TG2 activation via the PAC 1 receptor.
Modulation of protein kinase activity following PAC 1 receptor activation was assessed by Western blotting using phospho- ). PACAP-27 (100 nM) stimulated significant increases in ERK1/2 (Fig. 5A) , PKB (Fig. 5B ) and JNK1/2 (Fig. 5C ) phosphorylation in differentiating N2a cells. As expected PACAP-27-mediated increases in ERK1/2, PKB and JNK1/2 phosphorylation were inhibited by PD 98059 (50 lM; MEK1/2 inhibitor; Fig. 5A ), Akt inhibitor XI (0.1, 1 lM and 10 lM; PKB inhibitor; Fig. 5B ) and SP 600125 (20 lM; JNK1/2 inhibitor; Fig. 5B ), respectively. No significant increases in p38 MAPK phosphorylation were observed following PACAP-27 (100 nM for 10 min) treatment (data not shown). PACAP-27-induced increases in ERK1/2 were also attenuated by KT 5720 (5 lM; PKA inhibitor; Fig. 6A ) and Ro 31-8220 (10 lM; PKC inhibitor; Fig. 6B ), but not following removal of extracellular Ca 2+ (Fig. 6C) . In summary, these data have shown that PAC 1 receptor activation in differentiating N2a cells triggers robust increases in ERK1/2, PKB and JNK1/2 phosphorylation and that ERK1/2 activation is PKA and PKC dependent. The role of ERK1/2, PKB, PKC and JNK1/2 in PAC 1 receptorinduced TG2 activation was determined using pharmacological inhibitors of these protein kinases. PACAP-27-induced transglutaminase-mediated amine incorporation activity and protein cross-linking activity were inhibited by PD 98950, Ro 318220, and Akt inhibitor XI, suggesting the involvement of ERK1/2, PKC and PKB, respectively, in PAC 1 receptor-mediated TG2 responses (Fig. 7A-D) . In contrast, SP 6000125 attenuated PACAP-27-induced protein cross-linking activity (Fig. 7F ) but was without effect on TG2-mediated amine incorporation (Fig. 7E) . Finally, PD 98059, Ro 31-8220, Akt inhibitor XI, and SP 600125 had no significant effect on purified guinea pig liver TG2 activity (data not shown). Overall, these data suggest that the PAC 1 receptor stimulates TG2 activity in differentiating N2a cells via a multi protein kinase dependent pathway.
Visualisation of in situ TG2 activity following PACAP treatment
Biotin-X-cadaverine, is a cell penetrating primary amine, which enables the in situ visualisation of endogenous protein substrates of TG2, when combined with FITC-ExtrAvidin Ò [38] . PACAP-27
(100 nM) induced a time dependent and concentrationdependent (EC 50 = 6.7 ± 3 nM; pEC 50 = 8.3 ± 0.2; n = 3) increase in the incorporation of biotin-X-cadaverine into endogenous protein substrates of TG2 (Fig. 8) . Finally, the in situ responses to PACAP-27 were attenuated by the PAC 1 antagonist PACAP 6-38 and the TG2 inhibitors ZDON and R283 (Fig. 8) . Overall, these data indicate a similar pattern of TG2 activation in live cells. ( Fig. 9A and B) . The role of extracellular Ca 2+ in TG2 activation was assessed in the absence of extracellular Ca 2+ using nominally Ca 2+ -free Hanks/HEPES buffer containing 0.1 mM EGTA. Removal of extracellular Ca 2+ abolished PACAP-27-induced TG2 activation ( Fig. 9C and D) . These observations suggest that PAC 1 receptorinduced TG2 activation is dependent upon extracellular Ca 2+ .
Phosphorylation of TG2 following PAC 1 receptor activation
The effect of PAC 1 receptor activation on the phosphorylation status of TG2 was monitored via immunoprecipitation of TG2 followed by SDS-PAGE and Western blot analysis using antiphosphoserine and anti-phosphothreonine antibodies. PACAP-27 (100 nM) triggered a robust increase in the levels of TG2 phosphoserine and phosphothreonine (Fig. 10) . Pre-treatment with PD 98059 (50 lM; Fig. 10 ) and KT 5720 (5 lM; Fig. 11 ) attenuated PACAP-27 mediated increases in TG2 phosphorylation. In contrast, Ro 318220 (10 lM) had no significant effect (data not shown).
Finally, removal of extracellular Ca 2+ partially attenuated PACAP-27-induced TG2 phosphorylation (data not shown). These data indicate that activation of the PAC 1 receptor promotes robust increases in TG2 phosphorylation.
Role of TG2 in PAC 1 receptor-induced cell survival and neurite outgrowth
The role of TG2 in PAC 1 receptor-induced cell survival was determined in differentiating N2a cells following exposure of cells to simulated hypoxia (1% O 2 in glucose-free and serum-free medium). Initial experiments determined the time course of simulated hypoxia-induced cell death in differentiated N2a cells. Exposure of cells to simulated hypoxia (1% O 2 ) resulted in a time dependent decrease in MTT reduction, an increase in LDH release and activation of caspase 3 (Fig. 12) . A time period of 8 h hypoxia was used in subsequent experiments. Pre-treatment with PACAP-27 (100 nM; 10 min) significantly attenuated hypoxia-induced decrease in MTT reduction, release of LDH and activation of caspase-3 (Fig. 13) . Treatment with PACAP 6-38 (100 nM; 30 min) reversed PACAP-27 induced protection confirming the role of the PAC 1 receptor. Finally, the TG2 inhibitors R283 and Z-DON attenuated PACAP-27 induced cell survival (Fig. 14) . To validate these observations in another cell model the role of TG2 in PAC 1 receptorinduced cell survival in human SH-SY5Y neuroblastoma cells was also investigated. Initial experiments demonstrated that PACAP-27 treatment produced transient increases in TG2 catalysed biotin-cadaverine incorporation and protein cross-linking activity, peaking at 30 min ( Fig. 15A and C) . Furthermore, as shown in Fig. 15 , PACAP-27 stimulated concentration-dependent increases in biotin-amine incorporation activity (EC 50 = 2.2 ± 1.0 nM; p [EC 50 ] = 8.9 ± 0.4; n = 3) and protein cross-linking activity (EC 50 = 1.3 ± 0.5 nM; p[EC 50 ] = 9.0 ± 0.2; n = 3). Exposure of SH-SY5Y cells to simulated hypoxia (1% O 2 ) resulted in a time dependent decrease in MTT reduction, an increase in LDH release and activation of caspase 3 (data not shown), with 8 h used in subsequent experiments. As shown in Fig. 16 , pre-treatment with PACAP-27 (100 nM; 10 min) significantly attenuated hypoxiainduced decrease in MTT reduction, release of LDH and activation of caspase-3 in SH-SY5Y cells (Fig. 16) . Furthermore, PACAP 6-38 (100 nM; 30 min) reversed PACAP-27 induced protection confirming the role of the PAC 1 receptor in human SH-SY5Y cells (Fig. 16A-D) . Finally, the TG2 inhibitors R283 and Z-DON attenuated PACAP-27 induced cell survival (Fig. 16E-G) . Overall, these results demonstrate a role of TG2 in PAC 1 receptor-induced cell survival in both mouse N2a and human SH-SY5Y cells. The role of TG2 in PAC 1 receptor induced neurite outgrowth was assessed by monitoring the outgrowth of axon-like processes following 24 and 48 h treatment with PACAP-27 (100 nM). The TG2 inhibitors Z-DON (150 lM) and R283 (200 lM) attenuated outgrowth of axon-like processes following 24 h (data not shown) and 48 h treatment with PACAP-27, confirming the involvement of TG2 (Fig. 17) . These data confirm a role for TG2 in PAC 1 receptor mediated neurite outgrowth.
Discussion
The data in this report collectively suggest that PAC 1 receptormediated cell survival and neurite outgrowth are mediated by TG2, consistent with the view that TG2-mediated amine incorporation and protein cross-linking play important roles in these events.
In vitro modulation of TG2 transamidation activity by the PAC 1 receptor
Although the PAC 1 receptor is expressed in mitotic N2a cells [39, 50] its functional expression in differentiating N2a cells has to our knowledge not been reported. Hence, this study has demonstrated for the first time functional expression of the PAC 1 receptor in N2a cells induced to differentiate with retinoic acid. The neuropeptide PACAP mediates neurite outgrowth and neuroprotection; however, it is not known if these events involve PAC 1 receptor-induced TG2 activation [51, 42, 29] . TG2 can catalyse two types of transamidation, namely (i) intra-, and/or inter-molecular covalent cross-links between protein-bound glutamine and protein-bound lysine residues, and (ii) cross-links between primary amines and protein-bound glutamine [54] . In this study the PAC 1 receptor agonist PACAP-27 triggered time-and concentration-dependent increases in TG2-mediated biotincadaverine incorporation and protein cross-linking activity in differentiating N2a cells. The EC 50 values for PACAP-27 mediated transglutaminase-catalysed amine incorporation (0.08 nM) and protein cross-linking activity (0.4 nM) are in-line with the affinity of PACAP-27 for the PAC 1 receptor [17, 18, 28] . Furthermore, PACAP-27-induced TG2 activity was blocked by the PAC 1 receptor antagonist PACAP 6-38 [58] . Overall these data suggest that activation of TG2 by PACAP-27 is mediated via the PAC 1 receptor. It is important to note that PACAP 6-38 also displays high affinity for the VPAC 2 receptor [16] ; however, since the VPAC 2 agonist Bay 55-9837 did not trigger TG2 activity the effects of PACAP 6-38 are mediated entirely via the PAC 1 receptor. Finally, the PAC 1 receptor-induced increases in TG activity were inhibited by R283 and Z-DON, confirming that the observed increases in TG activity were via TG2. At present, very little is known regarding the regulation of TG2 enzymic activity by GPCRs. Examples in the literature include muscarinic receptor-mediated increases in TG2 activity in SH-SY5Y cells [78] and 5-HT 2A receptor-mediated transamidation (TGcatalysed) of the small G-protein Rac1 in the rat cortical cell line A1A1v [13] . The study by Zhang et al. [78] measured in situ TG2 activity (polyamine incorporation) triggered by the non-selective muscarinic agonist carbachol, whereas, Dai et al. [13] reported TG2 catalysed incorporation of 5-hydroxytryptamine into Rac1. 5-HT 2A receptor-mediated incorporation of 5-HT into the small GTPases RhoA and Rab4 has also been observed in platelets [75] . It was suggested that 5-HT 2A and muscarinic receptor-mediated release of Ca 2+ from intracellular Ca 2+ stores may be responsible for triggering TG transamidating activity [78, 75] . Our recent studies have shown that the G i/o -protein coupled A 1 adenosine receptor stimulates TG2 activation in H9c2 cardiomyocyte-like cells [74] . Since TG2 transamidase activity modulates protein function by cross-linking and incorporation of small molecule mono-and polyamines into protein substrates, it is likely that activation of TG2 by GPCRs plays a major role in the regulation of cellular function [54, 20] . ] can reach levels sufficient to activate TG2, for example in calcium microdomains that occur near the cell membrane following the opening of voltage gated Ca 2+ channels or near internal stores [6, 34] . Alternatively, the role of Ca 2+ in PAC 1
receptor-induced TG2 activation may require the sensitization of 
Role of protein kinases in PAC 1 receptor-mediated TG2 activation
The phosphorylation of TG2 by PKA inhibits its transamidating activity but augments its kinase activity [49] . These contrasting (100 nM) for 10 min prior to 8 h hypoxia (1% O 2 ) or 8 h normoxia. Cell viability was assessed by measuring the metabolic reduction of MTT by cellular dehydrogenases (panels A,E), release of LDH into the culture medium (panels B,F) and caspase-3 activity via Western blot analysis using anti-active caspase 3 antibody (panels C,G). Quantified caspase-3 activity data are shown in panels D and H. Data are expressed as a percentage of normoxia control cell values (=100%) and represent the mean ± S.E.M. from four independent experiments each performed in (A,E) quadruplicate and (B,F) sextuplicate. * P < 0.05, ** P < 0.01, *** P < 0.0001 and **** P < 0.0001, (a) versus normoxia control, (b) versus hypoxia control (c) versus 100 nM PACAP-27 in the presence of hypoxia.
effects on TG2 activity were obtained using histidine-tagged TG2 immobilized on nickel-agarose and incubated with the catalytic subunit of PKA. In this study the PKA inhibitors KT 5720 and RpcAMPs completely blocked PACAP-27-induced TG2 transamidating activity, which reflects PAC 1 receptor signalling via cAMP/PKA. The PAC 1 receptor also activates PLC/DAG/PKC (via G q -protein coupling) signalling and hence we determined the role of PKC. The broad spectrum PKC inhibitor Ro 318220 inhibited PACAP-27-induced TG2 activity, indicating that G q -protein coupling is involved in PAC 1 receptor-mediated TG2 activation. The PAC 1 receptor also activates ERK1/2, JNK1/2, p38 MAPK and PKB [51, 44, 8] . In this study we observed PACAP-27-induced activation of ERK1/2, JNK1/2, and PKB but not p38 MAPK. The MEK1/2 (upstream activator of ERK1/2) inhibitor PD 98059 blocked PACAP-27-induced TG2 activity, suggesting a prominent role for ERK1/2. These observations are comparable to A 1 adenosine receptor-mediated activation of TG2 in H9c2 cells, which was also sensitive to PKC and ERK1/2 inhibition [74] . In transfected HEK293 cells, PAC 1 receptor-induced ERK1/2 is dependent upon calcium influx and PLC/DAG/PKC [45] and hence the inhibition of PACAP-27-induced TG2 by removal of extracellular Ca 2+ and inhibition of PKC may reflect their up-stream role(s) in ERK1/2 activation. In the current study, PAC 1 receptor-induced ERK1/2 activation is independent of Ca 2+ influx and partially sensitive to PKC inhibition.
Similarly, PKA can activate ERK1/2 [65] and therefore the effect of PKA inhibitors on PAC 1 receptor TG2 activation may also reflect the up-stream role of PKA in ERK1/2 activation. In SH-SY5Y cells PAC 1 receptor-induced ERK1/2 activation is cAMP-dependent but PKAindependent [51] . However, in guinea-pig cardiac neurons [11] and N2a cells (the current study) PAC 1 receptor-induced ERK1/2 signalling is PKA-dependent. Hence, PKA-mediated inhibition of TG2 activation may indeed reflect the up-stream role of PKA in ERK1/2 activation. Finally, PACAP-27-induced TG2 activation was also sensitive to inhibition of PKB and JNK1/2, suggesting a role for these kinases in PAC 1 receptor-induced TG2 activation. We have previously shown that TG2 is phosphorylated following activation of the A 1 adenosine receptor in H9c2 cells [74] . The current data demonstrate that TG2 is also phosphorylated following PAC 1 [48] and at an unknown site(s) by PTEN-induced putative kinase 1 (PINK1; [47] ). At present the precise role of PAC 1 receptor-induced TG2 phosphorylation is not known. However, PKA-mediated phosphorylation of TG2 enhances its interaction with the scaffolding protein 14-3-3 and increases TG2 kinase activity, whereas PINK1-mediated phosphorylation of TG2 blocks its proteasomal degradation [48, 49, 47] . It is also conceivable that TG2 phosphorylation sensitizes TG2 to low levels of intracellular [Ca 2+ ] or alters its subcellular location. Work underway will determine the functional consequences of PAC 1 receptor-induced TG2 phosphorylation.
In situ visualisation of TG2 activity
Fluorescence microscopy was used to visualise in situ TG2 activity following PAC 1 receptor activation. The results were comparable to PAC 1 receptor-induced amine incorporation activity observed in vitro. However, given the covalent nature of biotin-Xcadaverine incorporation into protein substrates, it was surprising to observe that in situ TG2 activity returned to basal levels after 40 min. Possible explanations for this include reversal of amine incorporation by TG [64] , targeting of modified proteins for degradation or their rapid removal from the cell. Our previous studies have reported the rapid expulsion of biotinylated proteins from H9c2 cells following treatment with PMA or forskolin [1] . It could be that the rapid expulsion of biotinylated proteins from N2a cells occurs via exosomes [30] . Since N2a cells secrete exosomes it will be of interest to determine whether amine-labeled proteins can be detected in exosomes purified from cell culture supernatants obtained from these cells following PACAP-27 treatment [9] .
Role of TG2 in PAC 1 receptor-induced cytoprotection
Previous studies have shown that TG2 protects human SH-SY5Y neuroblastoma cells against heat shock-induced cell death [69] . Similarly, TG2 mediates protection of neuronal cells against hypoxia and oxygen/glucose deprivation-induced cell death by attenuating the HIF hypoxic response pathway [21] . Likewise, PACAP is widely recognized as a neuroprotective peptide and potential therapeutic agent for the treatment of cerebral ischaemia and various neurodegenerative disorders [57, 36] . The mechanisms of PACAP/PAC 1 receptor-induced neuroprotection are complex and involve multiple signalling pathways that include PKA, PKB, ERK1/2, NF-rB and Ca 2+ mobilization [44, 4, 42] . In this study we have shown for the first time a role for TG2 in PAC 1 receptorinduced cytoprotection in differentiating mouse N2a and human SH-SY5Y neuroblastoma cells. However, whilst it is not clear how PAC 1 receptor-induced TG2 activation mediates cell survival, TG2 is known to regulate pathways associated with PACAP neuroprotection. For example, TG2 activates adenylyl cyclase and enhances cAMP/PKA dependent CRE-reporter gene activity in SH-SY5Y neuroblastoma cells [68] and promotes NF-rB signalling via crosslinking of IrBa [20] . In the current study inhibition of TG2 blocked PACAP-27 mediated attenuation of hypoxia-induced activation of caspase-3. Recent studies have shown that TG2 inhibits apoptosis via the down-regulation of the Bax expression and inhibition of caspase 3 and 9 [10] . Further work is required to determine the role of TG2 in PAC 1 receptor-induced cell survival.
Role of TG2 in PAC 1 receptor-induced neurite outgrowth
Previous studies have shown that TG2 is essential for differentiation/neurite outgrowth in human neuroblastoma SHSY5Y cells [69, 61] . Mechanisms associated with TG2-induced neurite outgrowth include transamidation of RhoA and subsequent activation of ERK1/2 and p38 MAPK [61] . Similarly, PACAP triggers neuronal differentiation of human SH-SY5Y cells via a cAMP-dependent but PKA-independent pathway requiring activation of ERK1/2 and p38 MAPK [51] . The data presented in this study suggest that pharmacological inhibition of TG2 blocks PACAP-27-induced outgrowth of axon-like processes, suggesting the involvement of TG2 in PAC 1 receptor neurite outgrowth. However, further studies are required to identify the downstream substrates of TG2 and signalling pathways associated with the role of TG2 in PAC 1 receptor neuronal differentiation.
In conclusion, our data show for the first time that TG2 activity is regulated by the PAC 1 receptor in differentiating N2a and SH-SY5Y cells. Work is currently underway to understand more fully the role of TG2 in PAC 1 receptor signalling and modulation of neuronal cell function.
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